GlobeNewswire

New GMAT Exam Feature Offers Greater Control and Flexibility

Dela

Select Section Order Allows Test Takers to Customize Their GMAT Experience by Choosing the Section Order in which They Take the Exam

RESTON, Va., June 15, 2017 (GLOBE NEWSWIRE) -- In a continuing effort to enhance the GMAT exam experience for test takers, the Graduate Management Admission Council (GMAC) today announced the upcoming launch of Select Section Order, a new feature that will provide candidates the flexibility to customize their GMAT experience by choosing the section order in which they feel most comfortable taking the exam. Select Section Order will be available to test takers worldwide beginning July 11, 2017.

"The idea of being allowed to choose the section order had been commonly requested by test takers," said Ashok Sarathy, vice president, Product Management, GMAC. "We conducted a pilot in 2016 to test this feature and received overwhelmingly positive feedback, with 85 percent of participants surveyed expressing that this new feature boosted their confidence prior to even taking the exam. Our pilot findings also concluded that taking the exam in different section orders continues to maintain the quality and integrity of the GMAT scores."

The GMAT has four sections. When implemented on July 11, test takers will select their desired section order at the test center on exam date, immediately prior to the start of the exam. Test takers will be able to choose from three options:

  • Analytical Writing Assessment, Integrated Reasoning, Quantitative, Verbal (original order);
  • Verbal, Quantitative, Integrated Reasoning, Analytical Writing Assessment; or
  • Quantitative, Verbal, Integrated Reasoning, Analytical Writing Assessment.

These new changes are a continuation of the steps GMAC has implemented in recent years to enhance the test takers' GMAT experience, including:

  • the ability to cancel scores online after leaving the test center and the enhanced score reinstatement policies (March 2016),
  • removing cancelled scores from school score reports; allowing candidates to retake the GMAT exam after a 16-day time period rather than the previous 31-day retake period; and enabling test takers to access their Official Score Report online using their date of birth instead of an authentication code (July 2015),
  • introduction of the GMAT Enhanced Score Report, which provides test takers access to an in-depth analysis of their overall GMAT performance (January 2015), and
  • introduction of GMAT Score Preview, enabling test takers to preview their unofficial scores before deciding whether to report or cancel them (July 2014).

"The GMAT exam shows business schools that the test taker is serious about earning a graduate business degree and demonstrates the individual's commitment and readiness for the rigors of a graduate business program," said Sarathy. "Today, 9 out of 10 new MBA enrollments at the top 50 U.S. full-time MBA programs are made using a GMAT score."

About GMAC:  The Graduate Management Admission Council (GMAC) is a global, nonprofit association of 220 leading graduate business schools. Founded in 1953, we are actively committed to advancing the art and science of admissions by convening and representing the industry and offering best-in-class products and services for schools and students. GMAC owns and administers the Graduate Management Admission Test® (GMAT®) exam, used by more than 6,500 graduate programs worldwide, and the NMAT by GMAC(TM) exam, for entrance into graduate management programs in India. The Council is based in Reston, Va., with offices in London, New Delhi (Gurgaon) and Hong Kong. For information on assessments, study tools and services for candidates, visit www.mba.com. For information about The Council and our market intelligence, professional development opportunities and services for graduate management education, please visit www.gmac.com

MEDIA CONTACT:  
Jennifer Garfinkel; Director of Media Relations, GMAC
+1 (703) 668-9805 or jgarfinkel@gmac.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Graduate Management Admission Council via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Corline Biomedical AB: Patientrekrytering startar i Renaparin-studie30.11.2018 16:37Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att patientrekrytering i den kliniska fas 1-studien RENAPAIR-01 startar. I studien utvärderas bolagets läkemedelskandidat Renaparin® som är under utveckling för att förbättra utfallet av njurtransplantation. Patienter kommer inledningsvis att rekryteras på Akademiska sjukhuset i Uppsala. När de fyra första patienterna utvärderats inleds också rekrytering på Karolinska Universitetssjukhuset i Huddinge. Beskedet att patientrekrytering startar innebär att förberedelsearbetet inför studiestart är avslutat och att till exempel avtal, initieringsmöte, logistik, provhantering och monitorering är hanterat, samt att godkänt prövningsläkemedel nu finns tillgängligt för rekvirering av kirurgerna på transplantationskliniken i Uppsala för dosering till donatornjurar. När första patient doserats kommer detta meddelas separat. Corline har utvecklat och äger rättigheterna till Renaparin® som administreras direkt till den donerade njuren i

Stillfront: Bytro Labs lanserar en ny version av Supremacy 191427.11.2018 08:00Pressmeddelande

PRESSMEDDELANDE 2018-11-27 Bytro Labs, en studio inom Stillfront Group, lanserar en ny version av Supremacy 1914 Spelutvecklaren Bytro Labs, mest kända för sitt framgångsrika strategispel Call of War, har släppt en ny version av sin klassiska speltitel Supremacy 1914. Dagens lansering är den första av tre milstolpar för den nya versionen av Supremacy 1914 - The Great War som släpps 2019. Den första uppdateringen innehåller en komplett omarbetning av området för spelets community, ett nytt utseende för kartan samt ny 3D-teknologi. I nästa steg kommer Bytro Labs att gå vidare till "true cross platform" där spelet tillgängliggörs för fler plattformar, en strategi som tidigare har varit framgångsrik för titeln Call of War. Supremacy 1914 - The Great War släpps för Android senare i år och i början av 2019 släpps spelet för iOS och Steam. Det tredje och sista steget i lanseringen kommer i mitten av 2019 innehållande en större uppdatering avseende både innehåll och funktion, som färdigställer

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum